All Stories

  1. Effects of lifestyle and glucagon-like Peptide-1 receptor agonist-based therapies on waist circumference: A systematic review and meta-analysis
  2. Predicted cardiovascular risk reduction with tirzepatide vs. semaglutide: interpretative considerations from the SURMOUNT-5 post hoc analysis
  3. Global Bivariate Meta‐Analysis of FIB‐4 Cut‐Offs to Rule Out Advanced Fibrosis in MASLD
  4. Risk–Benefit Trade-offs of GLP-1RAs and SGLT-2is in Type 2 Diabetes Mellitus (T2D): Systematic Review, Meta-Analysis, and Net Benefit Modeling
  5. Optimising GLP-1RA Efficacy: A Meta-Analysis of Baseline Age and HbA1c as Predictors of MACE Reduction in T2DM
  6. Effects of Lifestyle and GLP-1RA based Interventions on Waist Circumference: A Systematic Review and Meta-Analysis
  7. Unveiling the Power of GLP-1RAs: Optimizing MACE Reduction in T2DM Through BMI and Blood Pressure Insights
  8. Understanding Weight Loss Treatments: Comparing New Medications for Obesity Management
  9. Forecasting Trial Milestones: A Predictive Analysis for Early Termination of the SOUL Study
  10. Forecasting Trial Milestones: A Predictive Analysis for Early Termination of the SOUL Study
  11. The Renal Composite Benefit of Sodium Glucose Co-Transporter 2 Inhibitors Should Ideally Be Assessed Based on a Standardised Definition: A Meta-Analysis of Randomised Controlled Trials
  12. Guide to Better Meta-Analysis: Checklists for Reviewers.
  13. Heterogeneity in cardiovascular death or hospitalization for heart failure benefits with flozins is linked to weight
  14. Assessing the Effects of Modern Renoprotective Agents in Preventing Progression of Renal Composite Outcomes in Patients with Type 2 Diabetes: A Network Meta-analysis
  15. Using machine learning to assess cardiovascular risk in T2DM patients without established cardiovascular disease: The MARK-2 analysis
  16. A Meta-Analysis of the Effect of Sodium Glucose Cotransporter-2 Inhibitors on Metabolic Parameters in Patients With Polycystic Ovary Syndrome
  17. The cardiovascular benefits of GLP1-RAs are related to their positive effect on glycemic control: A meta-regression analysis
  18. The cardiovascular benefits of GLP1-RA are directly related to their positive effect on glycaemic control: A meta-regression analysis
  19. A meta-analysis of the effect of sodium glucose cotransporter-2 inhibitors (SGLT-2is) on metabolic parameters in patients with polycystic ovary syndrome (PCOS)
  20. Testosterone replacement therapy in men with type 2 diabetes mellitus and functional hypogonadism –an Integrated Diabetes and Endocrine Academy (IDEA) consensus guideline
  21. A Target HbA1c Between 7 and 7.7% Reduces Microvascular and Macrovascular Events in T2D Regardless of Duration of Diabetes: a Meta-Analysis of Randomized Controlled Trials
  22. A target HbA1c between 7 – 7.7% reduces macrovascular events in T2D regardless of duration of diabetes – a meta-analysis of randomized controlled trials
  23. Meta‐analysis of the effects of sodium glucose cotransporter 2 inhibitors in non‐alcoholic fatty liver disease patients with type 2 diabetes
  24. Redefining Cardiovascular (CV) Death as a Primary Endpoint Component in Cardiovascular Outcome Trials
  25. Increase in the risk of type 2 diabetes during lockdown for the COVID19 pandemic in India: A cohort analysis
  26. “Compliance of the Indian National Task Force guidelines for COVID-19 recommendation by Indian doctors – A survey"
  27. Estimation of effects of nationwide lockdown for containing coronavirus infection on worsening of glycosylated haemoglobin and increase in diabetes-related complications: A simulation model using multivariate regression analysis
  28. Impact of complete lockdown on total infection and death rates: A hierarchical cluster analysis
  29. Linear Regression Analysis to predict the number of deaths in India due to SARS-CoV-2 at 6 weeks from day 0 (100 cases - March 14th 2020)
  30. Rapid sputum testing and not thermal screening alone should be the first-line screening test at airports: A Bayesian analysis
  31. Is it Worth CANVASing for CREDENCE? A Benefit-risk Analysis
  32. Impact of complete lock-down on total infection and death rates: A hierarchical cluster analysis
  33. Translating the statistical benefits of SGLT-2 inhibitors on cardio-renal outcomes into clinical practice
  34. The effect of angiotensin converting enzyme inhibitors and angiotensin receptor blockers on death and severity of disease in patients with coronavirus disease 2019 (COVID-19): A meta-analysis
  35. The role of corticosteroids in the management of critically ill patients with coronavirus disease 2019 (COVID-19): A meta-analysis
  36. Frequency of testing for COVID 19 infection and the presence of higher number of available beds per country predict outcomes with the infection, not GDP of the country – A descriptive statistical analysis
  37. Quantitative measure of asymptomatic cardiovascular disease risk in Type 2 diabetes: Evidence from Indian outpatient setting
  38. Teneligliptin and “Thorough QTc study”: thorough enough?
  39. Meta-analyses of the effects of DPP-4 inhibitors, SGLT2 inhibitors and GLP1 receptor analogues on cardiovascular death, myocardial infarction, stroke and hospitalization for heart failure
  40. Sodium-Glucose Cotransporter-2 Inhibitors (SGLT-2i) Reduce Hospitalization for Heart Failure Only and Have No Effect on Atherosclerotic Cardiovascular Events: A Meta-Analysis
  41. Liraglutide and Dulaglutide therapy in addition to SGLT-2 inhibitor and metformin treatment in Indian type 2 diabetics: a real world retrospective observational study
  42. Hypoglycaemia and CV risk: Perceptions and reality
  43. Is insulin degludec a more effective treatment for patients using high doses of insulin glargine but not attaining euglycemia? Some case reports from India
  44. India suspends pioglitazone: Is it justified?
  45. Treat-to-target trials in diabetes
  46. Pioglitazone – Do we really need it to manage type 2 diabetes?
  47. Polyendocrine syndromes (revision number 19)
  48. Hyperprolactinaemia (revision number 8)
  49. Pioglitazone—Do we really need it to manage type 2 diabetes?
  50. Hypercortisolism (revision number 36)
  51. Quantitative vibration perception threshold in assessing diabetic neuropathy: Is the cut-off value lower for Indian Subjects? [Q-VADIS Study]
  52. Critical appraisal of the recent data published on the link between insulin and cancer